

Alert card

Important safety information

Lojuxta[®] ▼ capsules
(lomitapide)

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the Yellow Card Scheme (www.mhra.gov.uk/yellowcard) or search for MHRA Yellow Card in the Google Play or Apple App Store for how to report side effects.

Please see section 4.5 of the Summary of Product Characteristics for the list of interactions with other medicines before giving the person named on this card any further medications. If you need to report an adverse event / side effects, have any questions or need a replacement card, please contact: Amryt Pharmaceuticals Medical Information on +800 4447 4447 or +44 1604 549 952 or e-mail medinfo@amrytpharma.com

Patient's name:

Doctor's name:

Doctor's phone number:

Date Lojuxta treatment started:

Information for the doctor or pharmacist

This patient has been prescribed Lojuxta.

Lojuxta could interact with the following drugs:

- CYP 3A4 inhibitors
- CYP 3A4 inducers
- Coumarin anticoagulants
- Statins
- P-gp substrates
- Oestrogen-containing oral contraceptives

Go to <https://www.medicines.org.uk/emc> to access the lomitapide SmPC.

Important safety information



Please keep this card with you at all times.

Show this card to any doctor or pharmacist involved in your treatment.

Please make sure that you have a list of all your other medicines with you, including herbal and non prescription medicines, when you visit your doctor or pharmacist.

© Amryt Pharma 2022. Lojuxta® is a registered trademark of the Amryt group. All rights reserved.

C-LOJ/UK/0033 – Date of preparation: December 2022